Accès gratuit
Numéro
Med Sci (Paris)
Volume 25, Numéro 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1011 - 1019
Section I - De la conception à la production
DOI https://doi.org/10.1051/medsci/200925121011
Publié en ligne 15 décembre 2009
  1. Amzel LM, Poljak RJ. Three-dimensional structure of immunoglobulins. Annu Rev Biochem 1979; 48 : 961–97.
  2. Saphire EO, Stanfield RL, Crispin MD, et al. Contrasting IgG structures reveal extreme asymetry and flexibility. J Mol Biol 2002; 319 : 9–18.
  3. Mariuzza RA, Phillips SE, Poljack RJ. The structural basis of antigen-antibody recognition. Annu Rev Biophys Biophys Chem 1987; 16 : 139–59.
  4. Mian IS, Bradwell AR, Olson AJ. Structure, function and properties of antibody binding sites. J Mol Biol 1991; 217 : 133–51.
  5. Oldstone MB. Molecular mimicry and immune-mediated diseases. FASEB J 1998; 12 : 1255–65.
  6. James LC, Roversi P, Tawfik DS. Antibody multispecificity mediated by conformational diversity. Science 2003; 299 : 1362–7.
  7. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7 : 715–25.
  8. Carter P. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6 : 343–57.
  9. Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 2008; 9 : 423–30.
  10. Teillaud JL. Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges. Exp Opin Biol Ther 2005; 5 : S1–13.
  11. Winter G, Milstein C. Man-made antibodies. Nature 1991; 349 : 293–9.
  12. Bourel D, Teillaud JL. Anticorps monoclonaux : tours et détours technologiques pour de nouveaux espoirs thérapeutiques. CR Biol 2006; 329 : 217–27.
  13. Hawkins RE, Russell SJ, Winter G. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol 1992;226 : 889–96.
  14. Coulon S, Pellequer JL, Blachère T, et al. Functional characterization of an anti-estradiol antibody by site-directed mutagenesis and molecular modelling: modulation of binding properties and prominent role of the V(L) domain in estradiol recognition. J Mol Recognit 2002; 15 : 6–18.
  15. Schier R, McCall A, Adams GP, et al. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol 1996; 263 : 551–67.
  16. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16 : 2825–33.
  17. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004; 104 : 1793–800.
  18. Jeyarajah DR, Thistlethwaite JR. General aspects of cytokine-release syndrome: timing and incidence of symptoms. Transplant Proc 1993; 25 : 16–20.
  19. Idusogie EE, Wong PY, Presta LG, et al. Engineered antibodies with increased activity to recruit complement. J Immunol 2001; 166 : 2571–5.
  20. Idusogie EE, Presta LG, Gazzano-Santoro H, et al. Mapping of the C1q binding site on Rituxan, a chimeric antibody with a human IgG1 Fc.J Immunol 2000; 164 : 4178–84.
  21. Shields RL, Namenuk AK, Hong K,et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R J Biol Chem 2001; 276 : 6591–604.
  22. Lazar GA, Dang W, Karki S, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 2006; 103 : 4005–10.
  23. Sibéril S, Dutertre CA, Boix C, et al. Molecular aspects of human FcgammaR interactions with IgG: functional and therapeutic consequences. Immunol Lett 2006; 106 : 111–8.
  24. Shields RL, Lai J, Keck R,et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc gamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277 : 26733–40.
  25. Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278 : 3466–73.
  26. Sibéril S, de Romeuf C, Bihoreau N, et al. Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc gamma R functions. Clin Immunol 2006; 118 : 170–9.
  27. Clynes RA, Towers TL, Presta LG., et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6 : 443–6.
  28. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004; 103 : 2738–43.
  29. Davies DR, Cohen GH. Interactions of protein antigens with antibodies. Proc Natl Acad Sci USA 1996; 93 : 7–12.
  30. Taylor R, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opinion Immunol 2008; 20 : 444–9.
  31. Umana P, Moessner E, Bruenker P, et al. Novel 3rd generation humanized type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction. ASH Annual Meeting Abstracts 2006; 108 : 229.
  32. Chan HT, Hughes D, French RR, et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into Triton-X100 insoluble membrane rafts. Cancer Res 2003; 63 : 5480–9.
  33. Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003; 101 : 1045–52.
  34. Weiner L, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet 2009; 373 : 1033–40.
  35. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomized, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373 : 633–40.
  36. Hommes DW, Mikhajlova TL, Stoinov Z, et al. Fontolizumab, a humanized anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn’s disease. Gut 2006; 55 : 1131–7.
  37. Skov L, beurskens FJ, Zachariae COC, et al. IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. J Immunol 2008; 181 : 669–79.
  38. Rossol M, Meusch U, Pierer M,et al. Interaction between transmembrane TNF and TNFR1/2 mediates the activation of monocytes by contact with T cells. J Immunol 2007; 179 : 4239–48.
  39. Emilie D. Effect on TNF antagonists on the T-lymphocyte response. Joint Bone Spine 2007;74 : 558–9.
  40. Bruns H, Meinken C, Schauenberg P,et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against mycobacterium tuberculosis in humans. J Clin Invest 2009; 119 : 1167–77.
  41. De Romeuf C, Dutertre CA, Le Garff-Tavernier M, et al. Chronic lymphocytic leukemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16. Br J Haematol 2008; 140 : 635–43.
  42. Lin H, Boesel KM, Griffith DT, et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 2004; 113 : 297–302.
  43. Ames SA, Gleeson CD, Kirkpatrick P. Omalizumab. Nat Rev Drug Disc 2004; 3 : 199–204.
  44. Arribas J, Borroto A. Protein ectodomain shedding. Chem Rev 2002; 102 : 4627–38.
  45. Giles FJ, Vose JM, Do KA, et al. Circulating CD20 and CD52 in patients with non-Hodgkin’s disease. Br J Haematol 2003; 123 : 850–7.
  46. Bidermann B, Gil D, Bowen DT, et al. Analysis of the CD33-related siglec family reveals that siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitors. Leuk Res 2007; 31 : 211–20.
  47. Beum PV, Kennedy AD, Williams ME, et al. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006; 176 : 2600–9.
  48. Klastersky J. Adverse effects of the humanized antibodies used as cancer therapeutics. Curr Opin Oncol 2006; 18 : 316–20.
  49. Agus DB, Gordon MS, Taylor C. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005; 23 : 2534–43.
  50. Schraven B, Kalinke U. CD28 superagonists: what makes the difference in humans ? Immunity 2008; 28 : 591–5.
  51. Loisel S, Ohresser M, Pallardy M, et al. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit Rev Oncol Hematol 2007;62 : 34–42.
  52. Behring E, Kitasato S. Über das Zustandekommen der Diphterie-Immunität und der Tetanus-Immunität bei Thieren. Dtsch Med Wochenschr 1890; 16 : 1113–4.
  53. Ducancel F. Quand la diversité du répertoire des immunoglobulines augmente ! Med Sci (Paris) 2003; 19 : 790–2.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.